此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Baricitinib (LY3009104) 在 COVID-19 (COV-BARRIER-PEDS) 患儿中的研究 (COV-BARRIER)

2026年7月18日 更新者:Eli Lilly and Company

Baricitinib 在 1 岁至 18 岁以下因 COVID-19 住院的儿科患者中进行的多中心、开放标签、药代动力学和安全性研究

本研究的目的是确定研究药物巴瑞克替尼对 2019 年冠状病毒病 (COVID -19) 住院儿科参与者是否有效和安全,并确定剂量。

研究概览

研究类型

介入性

注册 (实际的)

6

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Mexico City、墨西哥、04530
        • Instituto Nacional de Pediatría
      • Mexico City、墨西哥、06720
        • Hospital Infantil de México Federico Gómez
      • Campinas、巴西、13060-080
        • Instituto de Pesquisa Clínica de Campinas
      • Campinas、巴西、13034-685
        • Centro de Pesquisa São Lucas
      • Jaú、巴西、17201130
        • CECIP - Centro de Estudos do Interior Paulista
      • Porto Alegre、巴西、90410000
        • Hospital de Clinicas de Porto Alegre
      • Santo André、巴西、09080-110
        • Pesquisare Saúde
    • Florida
      • Orlando、Florida、美国、32806
        • Arnold Palmer Hospital for Children
    • Michigan
      • Detroit、Michigan、美国、48201
        • Children's Hospital of Michigan
    • Ohio
      • Cleveland、Ohio、美国、44106
        • University Hospitals Cleveland Medical Center
      • Madrid、西班牙、28041
        • Hospital Universitario 12 de Octubre
      • Madrid、西班牙、28046
        • Hospital Universitario La Paz
      • Pamplona、西班牙、31009
        • Complejo Hospitalario de Navarra
      • Vitoria-Gasteiz、西班牙、01009
        • Hospital Universitario de Araba (HUA)- Hospital Txagorritxu

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

2年 至 18年 (孩子、成人)

接受健康志愿者

不

描述

纳入标准:

  • 因冠状病毒 (SARS-CoV-2) 感染住院。
  • 1 至 <18 岁的男性或女性参与者。
  • 需要补充氧气并有胸部影像学检查结果,以在研究进入和注册后 72 小时内确认因 COVID-19 引起的呼吸系统疾病。
  • 补充氧气包括但不限于:鼻插管、面罩、高流量设备、CPAP/BiPAP、有创机械通气以及 ECMO。

排除标准:

  • 正在接受生物治疗(例如肿瘤坏死因子 [TNF] 抑制剂、白细胞介素抑制剂、T 细胞或 B 细胞靶向治疗、干扰素或 Janus 激酶 (JAK) 抑制剂);或正在接受其他免疫抑制剂,研究者认为参与该研究会使参与者处于不可接受的免疫抑制风险中。

注意:筛选前需要一个清除期。

  • 正在接受有机阴离子转运蛋白 3 (OAT3) 的强抑制剂(如丙磺舒),并且不能在研究开始时停药。
  • 诊断为当前活动性结核病 (TB) 或(如果已知)潜伏性结核病,并根据当地指南(仅根据病史,无需筛查测试)使用适当的抗结核疗法治疗不到 4 周。
  • 研究人员认为在服用研究产品时可能构成风险的疑似严重、活跃的细菌、真菌、病毒或其他感染(COVID-19 除外)。
  • 在筛选前 4 周内接种过任何活疫苗,或打算在研究期间接种活疫苗。 注意:所有参与者都可以使用非活性(灭活)疫苗接种。
  • 在研究开始时需要有创机械通气,包括体外膜肺氧合 (ECMO)。
  • 目前诊断为活动性恶性肿瘤,根据研究者的意见,在服用研究产品时可能构成风险。
  • 有静脉血栓栓塞 (VTE)(深静脉血栓形成 [DVT] 和/或肺栓塞 [PE])病史或被认为是 VTE 高风险 (DVT/PE)。
  • 预计在进入研究后 72 小时内出院,或转移到另一家非研究中心的医院(或另一单位)。
  • 有中性粒细胞减少症(绝对中性粒细胞计数 <1000 个细胞/微升)。
  • 有淋巴细胞减少症(绝对淋巴细胞计数 <200 个细胞/微升)。
  • 丙氨酸转氨酶 (ALT) 或天冬氨酸转氨酶 (AST) >5 倍 AAULN。
  • 估计肾小球滤过率 (eGFR)(肾脏疾病饮食改良 [MDRD])<40 毫升/分钟/1.73 平方米。
  • 已知对 baricitinib 或其任何赋形剂过敏。
  • 目前正在参加涉及调查产品的任何其他临床研究或被认为在科学或医学上与本研究不相容的任何其他类型的医学研究。 注意:在第 28 天之前,参与者不应参加(开始)另一项治疗 COVID-19 或 SARS CoV-2 的临床试验。
  • 怀孕,或打算在研究期间怀孕或哺乳。
  • 研究者或发起人认为存在免疫抑制风险或不适合纳入研究。
  • 正在使用或将使用体外血液净化 (EBP) 装置从血液中去除促炎细胞因子,例如细胞因子吸收或过滤装置,例如 CytoSorb®。
  • 是,在研究者看来,不太可能在筛选后存活至少 48 小时。

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Baricitinib QD
  • Participants received baricitinib as an oral suspension (2 milligrams per milliliter [mg/mL]) administered once daily (QD), with age group-based dosing: 4 milligrams (mg) for participants aged 10 to <18 years and up to 2 mg for those aged 1 to <10 years.
  • Treatment was administered for up to 14 days or until hospital discharge, whichever occurred first, with follow-up assessments through approximately Day 60.
口头给予
其他名称:
  • LY3009104

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC) of Baricitinib
大体时间:Day 1: 0.25, 0.5, 2-4 hours post-dose; Day 4: Pre-dose, 1, 6-10 hours post-dose
PK: Overall AUC of Baricitinib in pediatric participants with COVID-19. Summarized data were reported in this outcome measure.
Day 1: 0.25, 0.5, 2-4 hours post-dose; Day 4: Pre-dose, 1, 6-10 hours post-dose
PK: Maximum Concentration (Cmax) of Baricitinib
大体时间:Day 1: 0.25, 0.5, 2-4 hours post-dose; Day 4: Pre-dose, 1, 6-10 hours post-dose
PK: Overall Cmax of Baricitinib in pediatric participants with COVID-19. Summarized data were reported in this outcome measure.
Day 1: 0.25, 0.5, 2-4 hours post-dose; Day 4: Pre-dose, 1, 6-10 hours post-dose

次要结果测量

结果测量
措施说明
大体时间
Percentage of Participants Who Progressed to Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO]) by Day 28
大体时间:Day 1 to Day 28

NIAID-OS is an assessment of clinical status. The scale is as follows: 1)Not hospitalized, no limitations on activities; 2)Not hospitalized, limitation on activities and/or requiring home oxygen; 3)Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4)Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5)Hospitalized, requiring supplemental oxygen; 6)Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7)Hospitalized, on invasive mechanical ventilation or ECMO; 8)Death. NIAID-OS (range: 1-8); minimum value: 1 (not hospitalized, no limitations on activities); maximum value: 8 (death); higher scores indicate worse clinical status.

Progression to ventilation (only progressed excluding death) by Day 28 was defined as reaching NIAID-OS ≥6; for participants with baseline NIAID-OS 6, progression required NIAID-OS ≥7, and those with a baseline score of 7 were excluded.

Day 1 to Day 28
Percentage of Participants Who Died or Progressed to Non-Invasive Ventilation/High-Flow Oxygen, Invasive Mechanical Ventilation, or ECMO by Day 28
大体时间:Day 1 to Day 28

NIAID-OS is an assessment of clinical status. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. NIAID-OS (range: 1-8); minimum value: 1 (not hospitalized, no limitations on activities); maximum value: 8 (death); higher scores indicate worse clinical status.

Progression to ventilation (who died or progressed) by Day 28, defined as reaching a score ≥6; for baseline scores of 6 and 7, progression required scores ≥7 and Death (NIAID-OS=8).

Day 1 to Day 28
Percentage of Participants With at Least 1-Point Improvement on National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) or Live Discharge From Hospital
大体时间:Day 4, Day 7, Day 10, Day 14, and Day 28

NIAID-OS is an assessment of clinical status. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. NIAID-OS (range: 1-8); minimum value: 1 (not hospitalized, no limitations on activities); maximum value: 8 (death); higher scores indicate worse clinical status.

At each visit (Day 4/7/10/14/28), percentage of participants with ≥1-point improvement on NIAID-OS or discharged alive by that visit were reported in this outcome measure.

Day 4, Day 7, Day 10, Day 14, and Day 28
Number of Ventilator-Free Days (Days Free of Invasive Mechanical Ventilation)
大体时间:Day 1 to Day 28

NIAID-OS is an assessment of clinical status. The 8-point scale as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. NIAID-OS (range: 1-8); minimum value: 1 (not hospitalized, no limitations on activities); maximum value: 8 (death); higher scores indicate worse clinical status.

Number of ventilator free-days were defined as total number of days participants were alive and had NIAID-OS <7 point (free of invasive mechanical ventilation/ECMO) by Day 28.

Day 1 to Day 28
Time to Recovery
大体时间:Day 1 to Day 28

NIAID-OS is an assessment of clinical status. The 8-point scale as follows:1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. NIAID-OS (range: 1-8); minimum value: 1 (not hospitalized, no limitations on activities); maximum value: 8 (death); higher scores indicate worse clinical status.

Time to recovery was time from Day 1 to the first day the participant's maximum daily NIAID-OS was 1, 2, or 3. Participants who died before recovery were censored at Day 28 (not considered recovered).

Day 1 to Day 28
Percentage of Participants With Overall Improvement in the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 4
大体时间:Day 4

NIAID-OS is an assessment of clinical status. The 8-point scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. NIAID-OS (range: 1-8); minimum value: 1 (not hospitalized, no limitations on activities); maximum value: 8 (death); higher scores indicate worse clinical status.

Improvement was defined as the reduction from baseline in the NIAID-OS score, calculated as baseline score minus Day 4 score. A higher positive value indicates greater improvement.

Day 4
Percentage of Participants With Overall Improvement in the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 7
大体时间:Day 7

NIAID-OS is an assessment of clinical status. The 8-point scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. NIAID-OS (range: 1-8); minimum value: 1 (not hospitalized, no limitations on activities); maximum value: 8 (death); higher scores indicate worse clinical status.

Improvement was defined as the reduction from baseline in the NIAID-OS score, calculated as baseline score minus Day 7 score. A higher positive value indicates greater improvement.

Day 7
Percentage of Participants With Overall Improvement in the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 10
大体时间:Day 10

NIAID-OS is an assessment of clinical status. The 8-point scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen- no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. NIAID-OS (range: 1-8); minimum value: 1 (not hospitalized, no limitations on activities); maximum value: 8 (death); higher scores indicate worse clinical status.

Improvement was defined as the reduction from baseline in the NIAID-OS score, calculated as baseline score minus Day 10 score. A higher positive value indicates greater improvement.

Day 10
Percentage of Participants With Overall Improvement in the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 14
大体时间:Day 14

NIAID-OS is an assessment of clinical status. The 8-point scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen- no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. NIAID-OS (range: 1-8); minimum value: 1 (not hospitalized, no limitations on activities); maximum value: 8 (death); higher scores indicate worse clinical status.

Improvement was defined as the reduction from baseline in the NIAID-OS score, calculated as baseline score minus Day 14 score. A higher positive value indicates greater improvement.

Day 14
Percentage of Participants With Overall Improvement in the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 28
大体时间:Day 28

NIAID-OS is an assessment of clinical status. The 8-point scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen- no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. NIAID-OS (range: 1-8); minimum value: 1 (not hospitalized, no limitations on activities); maximum value: 8 (death); higher scores indicate worse clinical status.

Improvement was defined as the reduction from baseline in the NIAID-OS score, calculated as baseline score minus Day 28 score. A higher positive value indicates greater improvement.

Day 28
Duration of Hospitalization
大体时间:Day 1 to Day 28

NIAID-OS is an assessment of clinical status. The 8-point scale as follows:1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen- no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen- requiring ongoing medical care; 5)Hospitalized, requiring supplemental oxygen; 6)Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 7)Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. NIAID-OS (range:1-8); minimum value:1; maximum value:8; higher scores indicate worse clinical status.

Duration of hospitalization through Day 28 was defined as the total number of days with NIAID-OS scores of 4, 5, 6, or 7. Participants who died on or before Day 28 were assigned 28 days. For Day 1, hospitalization status was determined using worst NIAID-OS value recorded between baseline and the remainder of Day 1.

Day 1 to Day 28
All-Cause Mortality
大体时间:Baseline (Day 1) up to end of follow-up (up to Day 60)
Number of deaths by day 60 were reported in this outcome measure.
Baseline (Day 1) up to end of follow-up (up to Day 60)
Duration of Stay in the Intensive Care Unit (ICU) in Days
大体时间:Day 1 to Day 28
Duration of ICU stay through Day 28 was defined as the total number of days spent in the ICU through Day 28, with days following death counted up to Day 28. For participants alive at Day 28, duration was calculated as (Date of ICU discharge - Date of ICU admission) + 1. For participants who died in the ICU on or before Day 28, duration was calculated as (Date of death - Date of ICU admission + 1) + (Date of Day 28 - Date of death).
Day 1 to Day 28

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年12月21日

初级完成 (实际的)

2024年9月5日

研究完成 (实际的)

2024年11月4日

研究注册日期

首次提交

2021年10月8日

首先提交符合 QC 标准的

2021年10月8日

首次发布 (实际的)

2021年10月12日

研究记录更新

最后更新发布 (实际的)

2026年8月11日

上次提交的符合 QC 标准的更新

2026年7月18日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • 18253
  • I4V-MC-KHAB (其他标识符:Eli Lilly and Company)
  • 2021-001338-21 (EudraCT编号)
  • 2024-516824-32-00 (克蒂斯)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

在批准研究计划和签署数据共享协议后,将在安全访问环境中提供匿名的个人患者级别数据。

IPD 共享时间框架

在美国和欧盟研究的适应症首次公布和批准后 6 个月(以较晚者为准)可提供数据。 数据将无限期地可供请求。

IPD 共享访问标准

研究提案必须得到独立审查小组的批准,研究人员必须签署数据共享协议。

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅